Yutaka Domeki

Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer

Yukihiro Toi, Shunichi Sugawara, Jun Sugisaka et al. · JAMA Oncology · 2018 · 366 citations · Full text

Life Sciences, Immunology, Oncology +17

Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab

Yukihiro Toi, Shunichi Sugawara, Yosuke Kawashima et al. · The Oncologist · 2018 · 294 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer

Mari Aso, Yukihiro Toi, Jun Sugisaka et al. · The Oncologist · 2019 · 59 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab

Jun Sugisaka, Yukihiro Toi, Masataka Taguri et al. · JMA Journal · 2019 · 26 citations · Full text

Medicine, Oncology, Pharmacology +17

Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer

Kana Ono, Hirotaka Ono, Yukihiro Toi et al. · Cancer Medicine · 2021 · 19 citations · Full text

Medicine, Oncology, Pharmacotherapy +17